Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
03 2022
Historique:
received: 17 10 2020
accepted: 24 06 2021
pubmed: 14 7 2021
medline: 9 3 2022
entrez: 13 7 2021
Statut: ppublish

Résumé

In this study, we determined whether Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of In mice engrafted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, the tumour volumes of non-infected mice undergoing anticytotoxic T-lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccine treatments were significantly smaller than those of infected mice. We observed a decreased number and activation status of tumour-specific CD8 Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that

Identifiants

pubmed: 34253574
pii: gutjnl-2020-323392
doi: 10.1136/gutjnl-2020-323392
pmc: PMC8862014
doi:

Substances chimiques

Cancer Vaccines 0
Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-466

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: FG received honoraria for oral communication from Lilly, Sanofi, Amgen, and is an advisory board of Merck Serono, Amgen and Sanofi. The remaining authors declare no conflicts of interest.

Références

Front Immunol. 2016 Dec 12;7:573
pubmed: 28018343
Gut Microbes. 2021 Jan-Dec;13(1):1-22
pubmed: 33938378
Antimicrob Agents Chemother. 2003 Jul;47(7):2249-55
pubmed: 12821476
Gastroenterology. 2005 Jul;129(1):142-55
pubmed: 16012944
Microbiome. 2020 Oct 1;8(1):140
pubmed: 33004079
Am J Respir Crit Care Med. 2016 May 1;193(9):975-87
pubmed: 26630356
Cancer Immunol Immunother. 2020 Mar;69(3):343-354
pubmed: 31865400
iScience. 2020 Mar 27;23(3):100891
pubmed: 32114379
World J Gastroenterol. 2014 Jan 21;20(3):630-8
pubmed: 24574736
J Infect Dis. 2008 Aug 15;198(4):553-60
pubmed: 18598192
Inflamm Bowel Dis. 2015 Apr;21(4):854-61
pubmed: 25742401
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Int J Cancer. 2019 Oct 15;145(8):2021-2031
pubmed: 30458058
Immunity. 2019 May 21;50(5):1276-1288.e5
pubmed: 30902637
Gut. 2015 Sep;64(9):1368-78
pubmed: 25134787
J Clin Invest. 2011 Aug;121(8):3088-93
pubmed: 21737881
Front Oncol. 2015 Jan 15;4:385
pubmed: 25642417
Nat Med. 2020 Jun;26(6):919-931
pubmed: 32451498
J Immunol. 2018 Mar 1;200(5):1570-1579
pubmed: 29352004
Cancer Cell. 2018 Apr 9;33(4):570-580
pubmed: 29634945
Gastroenterology. 2009 Jun;136(7):2237-2246.e1
pubmed: 19272385
Inflamm Bowel Dis. 2010 Jun;16(6):1077-84
pubmed: 19760778
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467322
J Rheumatol. 2004 Aug;31(8):1546-50
pubmed: 15290733
Clin Exp Allergy. 2017 Oct;47(10):1331-1341
pubmed: 28802077
Immunity. 2018 May 15;48(5):992-1005.e8
pubmed: 29768180
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3047-52
pubmed: 23382221
J Clin Invest. 2012 Mar;122(3):1082-96
pubmed: 22307326
PLoS Pathog. 2019 Jun 12;15(6):e1007866
pubmed: 31188899
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Science. 2020 Sep 18;369(6510):1481-1489
pubmed: 32792462
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2021 Feb 5;371(6529):595-602
pubmed: 33542131
Mediators Inflamm. 2014;2014:426309
pubmed: 24587595
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Br J Cancer. 2018 Oct;119(8):950-960
pubmed: 30318514
Gastroenterology. 2011 Nov;141(5):1586-92
pubmed: 21762663
Mucosal Immunol. 2017 Jan;10(1):271-281
pubmed: 27143303
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11810-5
pubmed: 25074917
Genome Biol Evol. 2011;3:302-8
pubmed: 21402865
J Clin Invest. 2015 Aug 3;125(8):3297-302
pubmed: 26214524
Gut. 2020 Oct;69(10):1867-1876
pubmed: 32759302
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
Ann Oncol. 2019 Oct 1;30(10):1572-1579
pubmed: 31268133
World J Gastroenterol. 2014 May 21;20(19):5583-93
pubmed: 24914318
mBio. 2019 Mar 19;10(2):
pubmed: 30890606
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
Cell Rep. 2016 Feb 16;14(6):1395-1407
pubmed: 26854236

Auteurs

Paul Oster (P)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Laurie Vaillant (L)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Erika Riva (E)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Brynn McMillan (B)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Christina Begka (C)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Caroline Truntzer (C)

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.

Corentin Richard (C)

Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.

Marine M Leblond (MM)

Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Meriem Messaoudene (M)

Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.

Elisavet Machremi (E)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Emeric Limagne (E)

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.

Francois Ghiringhelli (F)

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.

Bertrand Routy (B)

Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.

Gregory Verdeil (G)

Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

Dominique Velin (D)

Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland dominique.velin@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH